Skip to main content
. 2022 Nov 28;37(11):2197–2203. doi: 10.1038/s41433-022-02315-9

Fig. 2. Fluorescein angiography images of a representative patient who received tocilizumab at baseline.

Fig. 2

A Early phase and B late phase, and 6th month of follow-up C early phase and D late phase.